TG Therapeutics rises as raised 2026 BRIUMVI revenue outlook continues to lift sentiment
TG Therapeutics shares rose as investors continued to price in the company’s newly raised 2026 revenue outlook driven by BRIUMVI. The company targets about $875–$900 million in 2026 total global revenue, including roughly $825–$850 million in BRIUMVI U.S. net product revenue.
1. What’s moving the stock today
TG Therapeutics (TGTX) traded higher Monday as the market continued to react to the company’s higher 2026 revenue targets and upbeat commercial trajectory for multiple sclerosis therapy BRIUMVI. Recent corporate communications laid out 2026 total global revenue of approximately $875–$900 million, with BRIUMVI U.S. net product revenue expected to be about $825–$850 million, reinforcing expectations for another year of rapid scale-up. (ir.tgtherapeutics.com)
2. The catalyst investors are keying on
The latest step-up in expectations centers on BRIUMVI’s 2025 exit momentum and management’s 2026 targets, which imply continued strong growth in U.S. net sales while the company advances development work on a subcutaneous formulation program. Investors are also factoring in capital-return signaling from prior buyback authorization alongside the higher outlook. (fool.com)
3. What to watch next
Near-term focus is on whether prescription/infusion demand and payer dynamics support the 2026 U.S. net revenue target, and whether spending tied to manufacturing and subcutaneous development stays within expectations. Options flow is also being monitored for positioning shifts as the stock moves. (fool.com)